Nonalcoholic fatty liver disease (NAFLD) is prevalent in people with the metabolic syndrome and type 2 diabetes and is present in up to one-third of the general population. Evidence is now accumulating that NAFLD is associated with obesity and diabetes and may serve as a predictor of cardiovascular disease (CVD). The possible mechanisms linking NAFLD and CVD include inflammation and oxidative stress, hyperlipidaemia, insulin resistance, and direct impact of NAFLD on coronary arteries and left ventricular dysfunction. In addition, several studies suggest that NAFLD is associated with high risk of CVD and atherosclerosis such as carotid artery wall thickness and lower endothelial flow-mediated vasodilation independently of classical risk factors and components of the metabolic syndrome. It is not yet clear how treatment of NAFLD will modulate the risk of CVD. Furthermore, studies are urgently needed to establish (i) the pathophysiology of CVD with NAFLD and (ii) the benefit of early diagnosis and treatment of CVD in patients with NAFLD. In the absence of biochemical markers, it is crucial that screening and surveillance strategies are adopted in clinical practice in the growing number of patients with NAFLD and at risk of developing CVD. Importantly, the current evidence suggest that statins are safe and effective treatment for CVD in individuals with NAFLD.

Background: Diabetic foot ulceration (DFU) is a major health problem across the globe. The objective of this study is to determine the prevalence of DFU and its associated risk factors in Sudanese individuals with diabetes.Methods: Three hundred and ten individuals with type 2 diabetes, who have been on treatment for DM for at least 1 year and volunteered to participate, were enrolled in this study. Participants were interviewed using standardized pretested questionnaire to record medical history, socio-demographic, life style characteristics and presence of DFU.Results: The prevalence of DFU was found to be 18.1% in this cohort (95% CI: 13.78-22.34%). Among different metabolic variants like hypertension, albuminuria, retinopathy, neuropathy, HbA1c, cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL) and triglyceride, only duration of diabetes was significantly associated with DFU (P<0.0018) as shown by logistic regression statistical analysis. Even after adjusting for all other potential risk factors, living with diabetes for more than 10 years is associated with an increase in the diabetic foot probability by 3.16 folds (95% CI: 052-10.48 folds increase), P=0.006.The adjusted effect for living with diabetes for more than 20 years on the diabetic foot complication probability is an increase by 1.73 folds (95% CI: 0.39-4.37 folds increase), P=0.005. However, living with diabetes for more than 5 years had a non-significant adjusted effect on diabetic foot probability.Conclusions: Prevalence of diabetic foot ulcer was 18.1 % and the risk of development of diabetic foot ulcer is increased with duration of diabetes more than 10 years.

BackgroundThe current challenge in managing people living with human immunodeficiency virus (PLWHIV) includes the identification and monitoring for comorbid health risks associated with HIV and its treatment and longer survival. Dyslipidemia, diabetes mellitus and metabolic syndrome are increasingly seen in PLWHIV.ObjectiveIn this narrative review, we aimed to summarize the current knowledge about diabetes, dyslipidemia and metabolic syndrome in PLWHIV in Africa and also to discuss the challenges that patients as well as health authorities in Africa may face.MethodsPubMed and Google scholar published-English literatures concerning earlier mentioned entities regardless of time limit were critically reviewed.ResultsThe prevalence of metabolic disorders in HIV population in Africa was estimated to range from 2.1% to 26.5% for diabetes and 20.2% to 43.5% for pre-diabetes, 13% to 58% for metabolic syndrome and 13% to 70% for dyslipidemia.ConclusionThe management of metabolic disorders and cardiovascular disease risks related to HIV is complex especially in Africa due to healthcare resources, but our experience suggests that metabolic clinic is beneficial to patients and staff and should be an important part of HIV services especially as the older HIV population is increasing. In this context, cardiovascular risk assessment of HIV-infected patients will become an important component of care in developing countries in Africa and strategies are needed to deal with progressive increase in the epidemic of type 2 diabetes, dyslipidemia and metabolic syndrome.

No abstract

No abstract

No abstract

No abstract

No abstract